Scarica l'app Stockscreener
27.03
1.41%
0.3796
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Pfizer Inc Borsa (PFE) Ultime notizie
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference - Business Wire
Pfizer stock slips in premarket as tariff jitters hit futures and weight-loss race resurfaces - Bez Kabli
Telescope Innovations Installs Second Self-Driving Lab at Pfizer - TMX Newsfile
Pfizer’s Comirnaty Update: What U.S. Patients Really Need to Know Now - AD HOC NEWS
Assessing Pfizer (PFE) Valuation As Investors Revisit Mixed Returns And Oncology Growth Prospects - simplywall.st
Massive News: Pfizer's 6% Dividend Could Be Safer Than You Think - Nasdaq
Stevens Capital Management LP Makes New Investment in Pfizer Inc. $PFE - MarketBeat
Pfizer Ltd: India Arm Pops on Strong Q3—But Is It a Buy for US Investors? - AD HOC NEWS
Pfizer: A Risky 6.3% Yield For Income-Oriented Investors - Seeking Alpha
Is Pfizer Stock an Underrated Healthcare Investment Play? - The Globe and Mail
Pfizer (PFE) Among Pharma Giants Securing Tariff Exemption - GuruFocus
Pfizer (PFE) Stock Falls to $26.59 as Barclays Sets $25 Target — Can Oncology Growth Offset Patent Loss Risks? - Swikblog
Barclays Initiates Coverage of Pfizer (PFE) with Underweight Recommendation - Nasdaq
AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026? - The Globe and Mail
This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Friday - Benzinga
Moderna Faces Lawsuit From BioNTech Over Next-Generation COVID-19 Shot - Benzinga
Barclays Initiates Coverage on Pfizer (PFE) with Underweight Rat - GuruFocus
Jupiter Asset Management Ltd. Raises Holdings in Pfizer Inc. $PFE - MarketBeat
Barclays Initiates Coverage on Pfizer With Underweight Rating - marketscreener.com
Barclays initiates Pfizer stock with underweight on patent losses - Investing.com
Moderna faces COVID vaccine patent suit from BioNTech (MRNA) - Seeking Alpha
Glucagon-like Peptide 1 (GLP-1) Market Report 2026-2035: Market to Reach $33.26 Billion by 2030 - GlobeNewswire Inc.
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Lowers Position in Pfizer Inc. $PFE - MarketBeat
Nicotine Gum Market Analysis Report 2026-2035: A $2.55 Billion Market by 2030 with Pfizer, GlaxoSmithKline, Haleon, Perrigo Co, and Johnson & Johnson Leading - Yahoo Finance
Pfizer Inc (PFE) Announces Positive Results from BREAKWATER Trial - Insider Monkey
Is Pfizer Stock the Only Big Pharma Name I'd Buy and Hold Through Any Market Crash? - Nasdaq
Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades) - Seeking Alpha
Pfizer (NYSE:PFE) Shares Down 1.8%Should You Sell? - MarketBeat
Pfizer's BRAFTOVI Trial Win Adds Weight To Undervalued Oncology Story - simplywall.st
Where is Pfizer Inc. (PFE) headed? - MSN
Muscle Invasive Bladder Cancer Market: Pharma Pipeline Fuels Rapid Expansion by 2034 – DelveInsight | CG Oncology, Pfizer, UroGen Pharma, Janssen R&D, Protara Therapeutics, Binhui Biopharmaceutical - Barchart.com
Pfizer’s BRAFTOVI BREAKWATER Trial Delivers Landmark Survival Gains in Colorectal Cancer - FinancialContent
Pfizer Targets Long-Term Oncology Growth Amid Competitive Pressure - TradingView
Where is Pfizer Inc. (PFE) Headed? - Insider Monkey
Pzena Investment Management LLC Boosts Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Seagen Is Gone From Nasdaq—Why the Pfizer Deal Still Matters to You - AD HOC NEWS
Axxcess Wealth Management LLC Boosts Stake in Pfizer Inc. $PFE - MarketBeat
First National Bank of Omaha Purchases New Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Ponders Viagra Lessons to Chart First Obesity Drug Launch - Bloomberg.com
Pfizer Just Flipped the Script: Why This Pharma Giant Matters to Your Wallet Now - AD HOC NEWS
Neuropsychiatry Market Is Going to Boom | Pfizer Inc. • Bristol-Myers Squibb • AstraZeneca - openPR.com
Pfizer (PFE) Experiences Mixed Options Sentiment Amid Downgrade - GuruFocus
Is There 25% Downside For Pfizer Stock? - Forbes
Pfizer Targets Real-World Myeloma Data in Taiwan With New Elranatamab Study - TipRanks
Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game - Seeking Alpha
Pfizer Colorectal Cancer Trial Win Adds Weight To Oncology Turnaround Story - Yahoo Finance
Pfizer (PFE) Valuation Check After Recent Share Price Rebound And Mixed Earnings Signals - Yahoo Finance Singapore
Sleep Aids Market 2026-2035 Top Key Playres: Pfizer (US), - openPR.com
Essex Financial Services Inc. Trims Stock Holdings in Pfizer Inc. $PFE - MarketBeat
CenterBook Partners LP Has $12.65 Million Holdings in Pfizer Inc. $PFE - MarketBeat
Advisors Capital Management LLC Purchases 260,742 Shares of Pfizer Inc. $PFE - MarketBeat
NEOS Investment Management LLC Purchases 223,163 Shares of Pfizer Inc. $PFE - MarketBeat
Skandinaviska Enskilda Banken AB publ Trims Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer’s BRAFTOVI Data Adds New Dimension To Oncology Growth Story - simplywall.st
Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer - Business Wire
Pfizer: The Rebound Looks Unsustainable (NYSE:PFE) - Seeking Alpha
Pfizer’s Braftovi Scores Again In Confirmatory Colorectal Cancer Trial - Citeline News & Insights
Mubadala Investment Co PJSC reports share stake in Pfizer, AbbVie, dissolves in Merck, Dell - marketscreener.com
Mubadala Investment Co Pjsc Reports Share Stake In Pfizer, Abbvie, Dissolves in Merck, Dell - TradingView
How Is The Market Feeling About Pfizer Inc? - Benzinga
Pfizer's Cancer Drug Combo Shows Strong Results In Key Colorecatal Cancer TrialPfizer (NYSE:PFE) - Benzinga
Pfizer's (PFE) Braftovi Shows Promise in Colorectal Cancer Trial - GuruFocus
Pfizer posts trial win for cancer therapy Braftovi (PFE:NYSE) - Seeking Alpha
Pfizer (PFE) Reports Positive Results from BREAKWATER Trial in m - GuruFocus
Pfizer Trial Updates Test Investor Views On Pipeline And Valuation - Yahoo Finance
Pfizer Inc. | Pharmaceuticals, Vaccines & Company History | Britannica Money - Britannica
Pfizer Inc. $PFE is PARK CIRCLE Co's 10th Largest Position - MarketBeat
Pfizer's Braftovi regimen improves progression-free survival in metastatic colorectal cancer - marketscreener.com
Rothschild & Co Redburn Adjusts Price Target on Pfizer to $25 From $23, Maintains Neutral Rating - marketscreener.com
M&G PLC Lowers Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Shell Asset Management Co. Has $1.03 Million Holdings in Pfizer Inc. $PFE - MarketBeat
15.89%
1.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):